Philadelphia University + Thomas Jefferson University
Sidney Kimmel Medical College
Department of Medicine

Jabbour, Serge

< Back

Profile

saj102

Serge A. Jabbour, DM, FACP, FACE

Contact Dr. Jabbour

Walnut Towers
211 S. Ninth Street, Suite 600
Philadelphia, PA 19107

(215) 955-1925
(215) 928-3160 fax

Medical School

St. Joseph's University, Beirut, Lebanon - 1993

Residency

Cooper Medical Center, Camden NJ

Fellowship

Thomas Jefferson University Hospital

Board Certification

Internal Medicine
Endocrinology, Diabetes & Metabolism

Hospital Appointment

Thomas Jefferson University Hospital
Methodist Hospital Division of Thomas Jefferson University Hospital

Awards & Honors

Philadelphia Magazine's Top Docs 2012, 2011

Publications

Most Recent Peer-Reviewed Publications

  1. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial
  2. Durability of response to dapagliflozin: a review of long-term efficacy and safety
  3. Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
  4. Erratum to: Musculoskeletal manifestations of primary hyperparathyroidism (Clinical Rheumatology, (2016), 35, 12, (3081-3087), 10.1007/s10067-016-3450-3)
  5. Evaluation and management of medullary thyroid cancer
  6. Diagnosis and management of thyroid lymphoma
  7. Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials
  8. Insulin degludec 200 Units/mL is associated with lower injection frequency and improved patient-reported outcomes compared with insulin glargine 100 Units/mL in patients with type 2 diabetes requiring high-dose insulin
  9. Musculoskeletal manifestations of primary hyperparathyroidism
  10. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial
  11. SGLT2 inhibitors
  12. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: A 24-week, multicenter, randomized, double-blind, placebo-controlled study
  13. Dapagliflozin in type 2 diabetes: Effectiveness across the spectrum of disease and over time
  14. An open label randomized phase II study of pasireotide with or without everolimus in castrate-resistant chemotherapy-naïve prostate cancer patients
  15. Incidence and Severity of Pancreatogenic Diabetes After Pancreatic Resection
  16. Dapagliflozin is effective as add-on therapy to sitagliptin with or withoutmetformin: A 24-Week, multicenter, randomized, double-blind, placebo-controlled study
  17. SGLT2 inhibitors to control glycemia in type 2 diabetes mellitus: A new approach to an old problem
  18. Comment and response to: Dapagliflozin-do we need it registered for type 2 diabetes?
  19. Collaboration designed to increase translation of diabetes research outcomes into clinical practice
  20. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor Dapagliflozin